Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

BACKGROUND: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. METHODS: In this randomised, controlled, open-label, adaptive platform tri...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884931/
https://www.ncbi.nlm.nih.gov/pubmed/33545096
http://dx.doi.org/10.1016/S0140-6736(21)00149-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884931/
https://www.ncbi.nlm.nih.gov/pubmed/33545096
http://dx.doi.org/10.1016/S0140-6736(21)00149-5

Ejemplares similares